Clover Biopharmaceuticals Ltd. has announced the termination of its cooperation with Adimmune Corporation. This decision, effective from June 30, 2025, comes after the company exercised its unilateral termination right under the Exclusive Agreement due to significant changes in market conditions. As a result, Clover will cease distribution of AdimFlu-S $(QIS)$ in mainland China. However, the Board of Clover Biopharmaceuticals assures that this termination will not adversely affect the company's operations. The Group remains focused on advancing its proprietary RSV vaccine candidate SCB-1019 for use in RSV re-vaccination settings and as part of a respiratory combination vaccine. Shareholders and potential investors are advised to exercise caution when dealing with the company's shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.